London +4420 814 42225
Moscow +7495 543 9194
Kiev +38044 599 2950

Our Clients

Order Informer

Home > News >

Evonik Industries increased its production capacity for amino acid glycine by 50 %

June 20/2011

(Evonik) -- Essen, Germany-based Evonik Industries has increased its production capacity for the pharmaceutical amino acid glycine by 50 percent due to rising demand. This was achieved by efficiency gains in the production process. Evonik is a major provider of glycine and manufactures the amino acid at its Chinese Nanning site in accordance with the strict requirements of cGMP (current Good Manufacturing Practice) and the European Pharmacopoeia (CEP; Certificate of Suitability of Monographs of the European Pharmacopoeia). Evonik is investing in a new plant in Nanning to expand its portfolio of specialty chemical products by milling and sieving processes. The new qualities are expected to come on the market at the end of the year.

By upgrading its technologies particularly in the purification process, Evonik has further improved product quality. "We're now able to provide glycine in all crystalline forms and particle size distributions requested by customers," notes Dr. Jean-Louis Philippe, the responsible marketing manager for the pharmaceutical amino acids.

Evonik is the creative industrial group from Germany. Evonik is active in over 100 countries around the world. In fiscal 2010 more than 34,000 employees generated sales of around EUR 13.3 billion and an operating profit (EBITDA) of about EUR 2.4 billion.

Category:General News
| More

Leave a comment

MRC help


 All News   News subscribe